Sarepta Therapeutics (SRPT) Moves Higher as Ex-FDA Official Sees Accelerated Approval
Tweet
Share
E-mailGet Alerts SRPT Hot Sheet
Join SI Premium – FREE
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is moving to the highs of the session and is nearly positive following a note from TheStreet's Adam Feuerstein on Twitter that Summer Street is saying a former FDA official is positive on accelerated approval for eteplirsen.
@adamfeuerstein
Summer Street call update: Former FDA official is POSITIVE on $SRPT receiving accelerated approval for eteplirsen.
After surging 200 percent on Wednesday on positive eteplirsen trial results, shares fell 16 percent on Thursday and were down another 7 percent moments ago before the call.
Shares of SRPT last traded at $37.50, down 1.1 percent.
@adamfeuerstein
Summer Street call update: Former FDA official is POSITIVE on $SRPT receiving accelerated approval for eteplirsen.
After surging 200 percent on Wednesday on positive eteplirsen trial results, shares fell 16 percent on Thursday and were down another 7 percent moments ago before the call.
Shares of SRPT last traded at $37.50, down 1.1 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Veraxa Biotech names Raju Willener as CFO
- Argo Graphene names battery scientist Al-Hallaj to board
- Dubai's VARA and Securitize sign MoU on tokenized markets
Create E-mail Alert Related Categories
Momentum Movers, Trader TalkRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
